NAMI - National Alliance on Mental Illness Home | About NAMI | Contact Us | En Espanol  | Donate  
  Advanced Search  

Sign In
Register and Join
What's New
State & Local NAMIs
Advocate Magazine
NAMI Newsroom
NAMI Store
National Convention
Special Needs Estate Planning
NAMI Travel

Top Story

Print this page
Graphic Site
Log Out
 | Print this page | 

FDA Hearing on Suicide Risk

December 19, 2006

Last week the Food and Drug Administration (FDA) held a hearing to examine if antidepressants pose a greater risk for an increase in suicide in adults. 

Officials at the FDA stated that the higher risk was found in patients 18 to 25, but that the risk faded among older patients.  This hearing is a follow-up hearing from one held two years ago on increased risk of suicide among children taking antidepressants.  The previous hearing resulted in a "black box" warning on the drug labels.

Bob Carolla, a NAMI consumer, testified in the hearing last week about his experiences with different antidepressants.  In his testimony he asked that the FDA "not impose barriers that discourage physicians from giving patients immediate, effective help when it is needed, or that undermine the national suicide prevention strategy."

Read an article written by Shankar Vedantam, of the Washington Post (opens in a new window, free registration might be required), on the hearing. 

NAMI’s medical director, Dr. Kenneth Duckworth, submitted testimony (PDF, opens in a new window) to the FDA in advance of the hearing.

Copyright Date: 12/19/2006

Post a Comment, Share on Facebook

 | Print this page | 


Support NAMI to help millions of Americans who face mental illness every day.

Donate today

Speak Out

Inspire others with your message of hope. Show others they are not alone.

Share your story

Get Involved

Become an advocate. Register on to keep up with NAMI news and events.

Join NAMI Today
Home  |  myNAMI  |  About NAMI  |  Contact Us  |  Jobs  |  SiteMap

Copyright © 1996 - 2011 NAMI. All Rights Reserved.